On March 11, Gelonghui Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has a wide range of pharmaceuticals. The main cardiovascular products include blood clotting dispersible tablets, Yixinshu granules, ginkgo biloba dispersible tablets, and captopril tablets. The company has always attached importance to investment in R&D, and regards R&D as the driving force for enterprise development. In the later stages, it will continue to increase R&D and innovation efforts according to R&D and market demand. The company's R&D focus is mainly on proprietary Chinese medicines: first, to continue to promote innovative traditional Chinese medicine drugs and improved new medicines to achieve marketing and sales goals as soon as possible; second, to develop specialty proprietary Chinese medicine products (such as cough tablets, skin disease blood poison pills, hypoglycemic pills, etc.) through clinical research or real-world research; third, to strengthen cooperation with research institutes and medical institutions to research and develop formulations in medical institutions with accurate curative effects.